



July 10, 2016

Dear CAHON members and friends,

Hope all is well.

I am writing to announce The CAHON Executive Team for 2016-2018. The formation of this dream team has been an absolute joy because there is no shortage of talented and committed members in our organization. I am proud to have assembled this group of diverse individuals who are eager to serve, and passionate about fulfilling the missions of CAHON. All of these individuals have been very active in the field of hematology and oncology. Their brief professional profiles appear below. More information about them will be found in their biographies soon to be posted on our CAHON website. I am sure that you agree with me that they collectively represent CAHON perfectly, with stellar accomplishments in all domains of Hem/Onc.

We are excited to hit the ground running. We will work together to advance the interests of our members and our organization. Committee chairs will be recruiting additional members to the committees. Together they will drive agenda and initiatives for the next two years. Most importantly, they will work with you and they depend on your support to carry out their function. At this point, we are anxious to hear from you what you want to see happen with CAHON. We are also looking forward to your continuing service as volunteers and advocators for CAHON in whatever way possible to bridge the gap between China and the United States in Hematology and Oncology.

With gratitude,

A handwritten signature in blue ink, appearing to read "Zihai Li".

Zihai Li, M.D., Ph.D.
President

Encl.

The CAHON Executive Team (2016-2018)

President: Zihai Li, M.D., Ph.D., *Medical University of South Carolina*

Vice president: Lei Zheng, M.D., Ph.D., *Johns Hopkins University*

Chair of the Board of Directors: Weijing Sun, M.D., *University of Pittsburgh*

Treasurer: Licheng (Richard) Xu, M.D., Ph.D., *Queens-Long Island Oncology*

- Academic Affairs Committee
Co-chairs:
Wei Ding, M.D., Ph.D., *Mayo Clinic*
Siwen Hu-Lieskovan, M.D., Ph.D., *University of California at Los Angeles*
- Clinical Affairs Committee
Co-chairs:
Mei Tang, M.D., *Berman Cancer Institute*
Peihua (Peggy) Lu, M.D., Ph.D., *Ludaopei Hospital*
- Publication Committee
Co-chairs
Bo Lu, M.D., Ph.D., *Thomas Jefferson University*
Hueiguo (Edward) Lin, M.D., *University of Washington*
- Industry Committee
Co-chairs:
Sen-hong (Sen) Zhuang, M.D., Ph.D., *Johnson & Johnson*
Steven Chin, M.D., *Eli Lilly and Company*
- Public Relation Committee
Co-chairs:
Ke Liu, M.D., Ph.D., *U.S. Food and Drug Administration*
Qiwei (Bill) Gai, M.D., Ph.D., *Life Point Hospital*
- Membership Committee
Co-chairs:
Hong Zheng, M.D., Ph.D., *Penn State University*
Yuxia Jia, M.D., Ph.D., *Penn State University*
- Events & Education Committee
Co-chairs:
Yiwu Huang, M.D., Ph.D., *Maimonides Medical Center*
Xinsheng (Michael) Liao, M.D., Ph.D., *Partner Oncology*
- Mentorship Committee
Co-chairs:
Yiping Yang, M.D., Ph.D., *Duke University*
TBD
- Finance Committee
Co-chairs:
TBD

Profiles of the Members of The 2016-2018 CAHON Executive Team

Steve Chin, M.D. (University of Arizona School of Medicine), Residency (Wayne State University School of Medicine), Hem/Onc fellowship (Wayne State University School of Medicine), the US Medical Lead for Gastrointestinal and H&N Oncology at Eli Lilly and Company. Selected honor and leadership roles: the lead investigator in GI research group, member of the phase I team and the lead clinician for the Cancer Cellular Therapy “Cabinet” at MUSC Center for Cellular Therapy. Director of NeuroPsycho-Oncology at Hollings Cancer center. Area of focus: Gastrointestinal and H&N Oncology.

Wei Ding, M.D. (Beijing Medical University), Ph.D. (Ohio State University), Residency and Hem/Onc fellowship (Mayo Clinic), associate professor of medicine and oncology at Mayo Clinic. Selected honors and leadership roles: member of NCI-CTEP, national PI for multiple trials, NCI-K23 awardee and LLS co-investigator. Area of focus: CLL and other hematological malignancies (Bone marrow environment, immunotherapy and PI3K/AKT pathway).

Qiwei (Bill) Gai, M.D. (Shan Dong Medical University), Ph.D. (Ohio University), Residency (St Luke's Hospital in St Louis), Hem/Onc fellowship (University of Maryland), attending hematologist and oncologist at Life Point Hospital in Danville Virginia, clinical adjunct assistant professor at the Virginia College of Osteopathic Medicine and Liberty University School of Osteopathic Medicine. Area of focus: general hematology and oncology, information technology

Siwen Hu-Lieskovan, M.D. (China Medical University), Ph.D. (University of Southern California), Residency (USC Medical Center), Hem/Onc fellowship (UCLA School of Medicine), assistant professor of medicine at the UCLA David Geffen School of Medicine. Selected honor and leadership roles: member of the NCI CTEP (Cancer Therapy and Evaluation Program) TVEC Project Team, study chair and translational lead of several SWOG immunotherapy trials against melanoma, ASCO Young Investigator Award and Career Development Award, ASCO Annual Meeting Merit Award, AACR Astra Zeneca Scholar In Training Award, AACR/ASCO MCCR Dan Von Hoff Best Protocol Development Award, Tower Cancer Research Foundation Grant. Area of focus: Melanoma, cancer immunotherapy (tumor immune microenvironment, biomarkers, combination strategies) and translational research.

Yiwu Huang, M.D. (Fujian Medical University), Ph.D. (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences), Residency (Staten Island University Hospital), Hem/Onc fellowship (Robert Wood Johnson Medical School), attending hematologist and oncologist at the Maimonides Medical Center. Selected honor and leadership roles: program director of Hematology-oncology Fellowship program and medical director of Asian Community Outreach in Maimonides Medical Center. Area of focus: general hematology and oncology.

Yuxia Jia, M.D. (Shanghai Medical University), Ph.D. (Tohoku University, Sendai Japan), Residency (Stony Brook University), Hem/Onc fellowship (Columbia University), assistant professor of medicine at the Penn State Hershey Cancer Institute. Selected honor and leadership roles: senior leader of GI Oncology Program at the Penn State Hershey Cancer Institute. Area of focus: gastrointestinal malignancies.

Zihai Li, M.D. (Henan Medical University), Ph.D. (Mount Sinai School of Medicine), Residency (Montefiore Medical Center of the Albert Einstein College of Medicine), Hem/Onc fellowship (University of Washington - Fred Hutchinson Cancer Research Center), professor of medicine, microbiology and immunology at the Medical University of South Carolina (MUSC). Selected honor and leadership roles: Chair of Dept of Microbiology and Immunology, MUSC, South Carolina SmartState Endowed Chair in Stem Cell Biology and Therapy, leader of the Hollings Cancer Center Cancer Immunology Program, elected member of the American Society of Clinical Investigation (ASCI), clinical scholar of Leukemia and Lymphoma Society, member of NIH Innate Immunity and Inflammation Study Section, member of ASCO Program Committee and track leader of the Developmental Therapeutics and Translational Research – Immunotherapy, co-editor-in-chief of *Exp Hematol Oncol*. Area of focus: cancer immunotherapy, regulatory T cell biology, innate immunity, heat shock protein vaccine and biology, unfolded protein response.

Xinsheng (Michael) Liao, M.D. (West China Univ. of Medical Sciences), Ph.D. (University of Texas Southwestern Med. Center), Residency (Brown University), Hem/Onc fellowship (University of Washington - Fred Hutchinson Cancer Research Center), attending hematologist and oncologist at the Partner Oncology, Inc. Selected honor and leadership roles: CUSBEA Student Award, Irvington Medical Foundation fellowship. Area of focus: general hematology and oncology.

Huiguo (Edward) Lin, M.D. (China Medical University), Residency (Brown University), Hem/Onc fellowship (Beth Israel Deaconess Medical Center, Harvard Medical School), associate professor of medicine at the University of Washington, associate member at the Fred Hutchinson Cancer Research Center. Selected honor and leadership roles: member of NCCN UICC Sino-US committee, editor-in-chief of Cancer-matrix Manual, member of the editorial

board for Stem Cell, Translational Medicine and the president of Seattle Biomedical Association. Area of focus: colorectal cancer, cancer stem cells and endothelial progenitors.

Ke Liu, M.D. (Henan Medical University), Ph.D. (Cornell University), Residency (Long Island Jewish Medical Center), Hem/Onc fellowship (National Cancer Institute), chief of oncology at the Center for Biologics Evaluation and Research (CBER) of U.S. Food and Drug Administration. Area of focus: immunotherapy, gene and cellular therapy of cancer, regulations and clinical trials design.

Bo Lu, M.D. (Shanghai/Fudan Medical University), Ph.D. (Baylor School of Medicine), Residency (University of Southern California School of Medicine), Rad Onc fellowship (University of Rochester Medicine & Dentistry), professor of radiation oncology at Thomas Jefferson University. Selected honor and leadership roles: translational research chair of the RTOG/NRG Lung Cancer Committee and chair for the NCI Lung Cancer Working Group, past director of the Translational Research Program and Lung Cancer Research Program at the Vanderbilt University Medical Center. Area of focus: lung cancer, radiosurgery, mechanism of radioresistance, cancer stem cells, radio-immunotherapy and biomarkers.

Peihua (Peggy) Lu, M.D. (Peking University Medical School), Residency (University of Nebraska Medical Center), Hem/Onc fellowship (Stanford University), vice president of Ludaopei Hospital. Selected honor and leadership roles: director of Lymphoma and Multiple Myeloma Center, director of Hem/Onc Department, past NCI-K011 awardee, America's top oncologist in 2012. Area of focus: multiple myeloma and lymphoma (clinical service and research).

Weijing Sun, M.D. (Shanghai Medical University), Residency (Loyola University), Hem/Onc fellowship (University of Pennsylvania), professor of medicine at the University of Pittsburgh Medical Center. Selected honors and leadership roles: director of GI cancer Hem/Onc division, member of NCI GI Steering Committee Hepatobiliary Task Force, member of ECOG GI Core Committee, member of the ASCO Membership Committee. Area of focus: GI malignancies, clinical research, Phase I/II trials.

Mei Tang, M.D. (Shanghai Medical University), Residency (Greater Baltimore Medical Center), Hem/Onc fellowship (University of Maryland Medical System), attending hematologist and oncologist at the Berman Cancer Institute. Selected honor and leadership roles: member of the NCI Head and Neck Cancer Metastatic Disease Task Force, board member of the Maryland and District of Columbia Society of Clinical Oncology (MDSCO), board member of the Chinese American Doctors Association (CADA). Area of focus: clinical research in H&N cancer and lung cancer, general hematology and oncology.

Licheng (Richard) Xu, M.D. (Anhui Medical University), Ph.D. (Dartmouth College), Residency (Long Island Jewish Medical Center), Hem/Onc fellowship (Memorial-Sloan Kettering Cancer Center), attending hematologist and oncologist at the Queens-Long Island Oncology & Hematology. Selected honor and leadership roles: The Howard Hughes Medical Institute Physician-Scientist Training Grant awardee, regular commentator and writer for Sing Tao Daily. Area of focus: general hematology and oncology.

Yiping Yang, M.D. (Zhejiang Medical University), Ph.D. (University of Michigan), Residency (University of Pennsylvania), Hem/Onc fellowship (Johns Hopkins), professor of medicine and immunology at Duke University. Selected honor and leadership roles: co-leader of Duke Cancer Institute, Hematological Malignancies and Cellular Therapy Program, associate editor of Journal of Clinical Investigation (JCI), elected member of the American Society of Clinical Investigation (ASCI). Area of focus: innate immunity and NK cells, regulatory T cells and tumor microenvironment, T cell memory and immunotherapy of hematological malignancies.

Hong Zheng, M.D. (Capital Medical University), Ph.D. (University of Connecticut School of Medicine), Residency (Penn State Hershey Medical Center), Hem/Onc fellowship (Yale University), assistant professor of medicine at the Penn State Hershey Cancer Institute. Selected honor and leadership roles: Christian Jacobsen Post-Doctoral Fellowship Award, American Society of Hematology (ASH) Scholar Award. Area of focus: hematological malignancies, hematopoietic stem cell transplantation, transplantation immunology and developmental therapeutics for leukemia.

Lei Zheng, M.D. (Peking Union Medical College), Ph.D. (University of Texas Health Science Center at San Antonio), Residency (Long Island Jewish Medical Center), Hem/Onc fellowship (Johns Hopkins), associate professor of medicine, oncology and surgery at Johns Hopkins. Selected honor and leadership roles: Past NCI K23 awardee, multiple NIH R01 grant awardee, PI or sponsor of 6 investigator initiated clinical trials, member for the NCI Grant Review Subcommittee J, founding member and chair of the Board of Directors of Chinese American Physicians Association (CADA), founding board member of Asian American Healthcare Center (AAHC). Area of focus: clinical

development of novel immunotherapies for gastrointestinal cancers (GVAX vaccine, tumor microenvironment, immune reprogramming, novel oncogenic targets).

Sen-hong (Sen) Zhuang, M.D. (Sun Yat-Sen University of Medical Sciences), Ph.D. (University of Miami School of Medicine), Residency (Long Island Jewish Medical Center), Hem/Onc fellowship (National Cancer Institute), vice president of the Clinical Oncology Research Program at Johnson & Johnson. Selected honor and leadership roles: the clinical head of the Hematology Disease Area Stronghold, leader for the global clinical development of YONDELIS (soft tissue sarcoma and ovarian cancer), DOXIL (multiple myeloma and breast cancer), ZARNESTRA (acute myelogenous leukemia and myelodysplastic syndrome), Senicapoc (sickle cell anemia), HDAC inhibitor, HDM-2 inhibitor, FGR Inhibitor programs, ZYTIGA and others. Area of focus: global clinical development of hematologic assets such as ibrutinib (IMBRUVICA) and daratumumab.